Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
In the year-ago quarter, Kymera reported a loss of 70 cents per share. Collaboration revenues totaled $10.3 million, which missed the Zacks Consensus Estimate of $12 million. Revenues increased 8.7% from the year-ago quarter's level. Collaboration revenues in the first quarter were attributable to the company's association with bigwig Sanofi SNY. Shares of KYMR have surged 42.6% year to date against the industry's decline of 7.6%. Image Source: Zacks Investment Research Quarter in Detail Research and development expenses amounted to $48.8 million, up 15.6% year over year. This was due to increased expenses related to the investment in the company's proprietary targeted protein degradation platform and discovery programs, as well as a rise in occupancy and related costs due to continued growth in the research and development organization. General and administrative expenses totaled $14.4 million, up 14.4% year over year due to an increase in legal and professional service
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual MeetingGlobeNewswire
- Kymera Therapeutics to Participate in Upcoming May Investor ConferencesGlobeNewswire
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 5/2/24 - Beat
KYMR
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- 4/24/24 - Form ARS
- KYMR's page on the SEC website